Xencor/$XNCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xencor
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Ticker
$XNCR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
250
ISIN
US98401F1057
Website
Xencor Metrics
BasicAdvanced
$598M
-
-$3.05
0.87
-
Price and volume
Market cap
$598M
Beta
0.87
52-week high
$26.42
52-week low
$7.16
Average daily volume
873K
Financial strength
Current ratio
5.894
Quick ratio
5.737
Long term debt to equity
25.946
Total debt to equity
34.726
Interest coverage (TTM)
-4.62%
Profitability
EBITDA (TTM)
-152.834
Gross margin (TTM)
-80.30%
Net profit margin (TTM)
-163.17%
Operating margin (TTM)
-129.37%
Effective tax rate (TTM)
-0.95%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-11.42%
Return on equity (TTM)
-34.05%
Valuation
Price to revenue (TTM)
4.5
Price to book
0.93
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-3.339
Free cash flow yield (TTM)
-29.95%
Free cash flow per share (TTM)
-251.55%
Growth
Revenue change (TTM)
-25.88%
Earnings per share change (TTM)
27.24%
3-year revenue growth (CAGR)
-26.97%
10-year revenue growth (CAGR)
30.58%
3-year earnings per share growth (CAGR)
19.66%
10-year earnings per share growth (CAGR)
17.75%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Bulls say / Bears say
Xencor's strategic partnerships, including a restructured agreement with Genentech that could yield up to $600 million in milestones, enhance its financial stability and extend its cash runway into 2027. (markets.businessinsider.com)
The company's focus on T-cell engagers is validated by promising data from Amgen's AMG509, developed using Xencor's technology, indicating potential for significant advancements in cancer treatment. (markets.businessinsider.com)
Analysts maintain a 'Strong Buy' consensus rating for Xencor, with an average price target of $38.75, suggesting a potential upside of over 100% from current levels. (markets.businessinsider.com)
StockNews.com downgraded Xencor's rating from 'hold' to 'sell' in March 2025, indicating potential concerns about the company's near-term performance. (marketbeat.com)
Despite better-than-expected earnings, Xencor reported a net loss of $53.48 million in Q4 2024, reflecting ongoing financial challenges. (marketbeat.com)
The company's stock price has experienced significant volatility, trading as low as $12.69 and as high as $27.24 over the past year, which may concern risk-averse investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xencor stock?
Xencor (XNCR) has a market cap of $598M as of June 27, 2025.
What is the P/E ratio for Xencor stock?
The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of June 27, 2025.
Does Xencor stock pay dividends?
No, Xencor (XNCR) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Xencor dividend payment date?
Xencor (XNCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Xencor?
Xencor (XNCR) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.